全文获取类型
收费全文 | 16959篇 |
免费 | 961篇 |
国内免费 | 143篇 |
专业分类
耳鼻咽喉 | 105篇 |
儿科学 | 314篇 |
妇产科学 | 466篇 |
基础医学 | 2285篇 |
口腔科学 | 418篇 |
临床医学 | 1225篇 |
内科学 | 4914篇 |
皮肤病学 | 275篇 |
神经病学 | 1511篇 |
特种医学 | 692篇 |
外科学 | 2443篇 |
综合类 | 39篇 |
一般理论 | 3篇 |
预防医学 | 616篇 |
眼科学 | 184篇 |
药学 | 952篇 |
中国医学 | 23篇 |
肿瘤学 | 1598篇 |
出版年
2023年 | 107篇 |
2022年 | 187篇 |
2021年 | 483篇 |
2020年 | 239篇 |
2019年 | 380篇 |
2018年 | 456篇 |
2017年 | 324篇 |
2016年 | 377篇 |
2015年 | 424篇 |
2014年 | 638篇 |
2013年 | 830篇 |
2012年 | 1183篇 |
2011年 | 1209篇 |
2010年 | 756篇 |
2009年 | 673篇 |
2008年 | 1167篇 |
2007年 | 1181篇 |
2006年 | 1093篇 |
2005年 | 1152篇 |
2004年 | 1082篇 |
2003年 | 1003篇 |
2002年 | 882篇 |
2001年 | 124篇 |
2000年 | 93篇 |
1999年 | 152篇 |
1998年 | 201篇 |
1997年 | 150篇 |
1996年 | 160篇 |
1995年 | 122篇 |
1994年 | 135篇 |
1993年 | 113篇 |
1992年 | 98篇 |
1991年 | 87篇 |
1990年 | 79篇 |
1989年 | 62篇 |
1988年 | 53篇 |
1987年 | 46篇 |
1986年 | 59篇 |
1985年 | 54篇 |
1984年 | 48篇 |
1983年 | 41篇 |
1982年 | 48篇 |
1981年 | 55篇 |
1980年 | 38篇 |
1979年 | 30篇 |
1978年 | 10篇 |
1977年 | 11篇 |
1976年 | 14篇 |
1975年 | 11篇 |
1970年 | 10篇 |
排序方式: 共有10000条查询结果,搜索用时 406 毫秒
51.
Two-step endoscopic resection of gastric leiomyomas 总被引:2,自引:0,他引:2
Pasquale Spinelli Federico G. Cerrai Antonino R. Cambareri Emanuele Meroni Paolo Pizzetti 《Surgical endoscopy》1993,7(2):90-92
Summary Our two-step technique for endoscopic treatment of gastric leiomyomas is illustrated. From January 1979 to June 1991, nine symptomatic patients with sessile leiomyomas of the stomach were treated at the Endoscopy Division of Istituto Nazionale Tumori, Milan.The diagnosis was achieved by means of endoscopic observation of the lesion and, when possible, by ultrasound endoscopy.This new technique consists of first removing superficial portion of the tumor by electrosurgical snare. Second, a cleavage plane is found within the proper muscle layer; the tumor is enucleated as much as possible by tightening the snare around it and creating a pseudo-stalk. No major complication occurred nor were any recurrences observed at 21.8 months in the 7/9 patients treated by endoscopy alone. Endoscopic therapy was performed on an outpatient basis and only large lesions required short hospitalization. 相似文献
52.
Carla Testorell Carlo Pruneri Luigi Ferini-Strambi Marco Zamperetti Carlo A. Altamura Salvatore Smirne Silvio R. Bareggi 《Human psychopharmacology》1993,8(6):423-428
Serum immunoglobulins and the activity of natural killer (NK) cells of 50 epileptic patients (eight with idiopathic generalized epilepsy and 42 with cryptogenic partial epilepsy) and 28 controls have been studied. The values of IgA, IgG and IgM were the same-in patients and controls. The NK activity in controls was linearly related to the effector-to-target ratio, but this linear relationship was not observed in epileptic patients. The cytotoxic activity of NK cells at the lowest effector-to-target ratio was significantly greater in patients than in controls. This increase was observed in each therapy group. Our results seem to confirm a disturbance of the immune system in epileptic patients and suggest that this modification of cellular immunity is not a drug effect but is related to the illness itself. 相似文献
53.
54.
Teresa Coccini Luciano Maestri Francesco S. Robustelli della Cuna L. Bin Lucio G. Costa Luigi Manzo 《Archives of toxicology》1996,70(11):736-741
Styrene is stereoselectively oxidized by cytochrome P450 to its reactive metabolite, styrene oxide. The (R)- and (S)-enantiomers
of styrene oxide can be conjugated with glutathione (GSH) to both (R)- and (S)-diastereoisomers of the specific mercapturic
acids, N-acetyl-S-(1-phenyl-2-hydroxyethyl)-L-cysteine (M1) and N-acetyl-S-(2-phenyl-2-hydroxyethyl)-L-cysteine (M2). Several investigations have indicated different toxic potential of the (R)- and (S)-configurations of styrene
oxide and its GSH- and N-acetyl-conjugates. In this study the mercapturic acid diastereoisomers were measured in the urine
of rats exposed to styrene in combination with ethanol, a good inducer of styrene metabolism. Male Sprague-Dawley rats were
given an isocaloric liquid diet containing ethanol (5% w/v) for 3 weeks. Starting from the 2nd week, the animals were also
exposed to styrene vapours (300 ppm, 6 h/day, 5 days/week) in a dynamic exposure chamber. Both the (R)- and (S)-diastereoisomers
of the M1 and M2 as well as the conventional biomarkers, mandelic acid (MA) and phenylglyoxylic acid (PGA) were measured in
urinary samples. Approximately 30 and 25% reduction of the levels of brain non-protein sulfhydryls (NPS) was observed in the
animals given styrene and ethanol, respectively, while the combined ethanol and styrene treatment resulted in a 60% decrease.
Ethanol consumption also resulted in higher urinary levels of the M1-R, M1-S and M2 metabolites associated with increased
M1-R/S ratio and higher urinary MA excretion compared to animals treated with styrene. These results suggest that the urinary
mercapturic acid diastereoisomers may be used as a noninvasive tool to examine stereoselective patterns of styrene metabolism
in vivo, as well as their alterations caused by ethanol. These compound-specific mercapturic acids may also be valuable indicators
of styrene-induced disorders of GSH homeostasis in nonaccessible organs.
Received: 19 December 1995/Accepted: 10 May 1996 相似文献
55.
Prevalence of hereditary ataxias and spastic paraplegias in Molise,a region of Italy 总被引:8,自引:0,他引:8
Alessandro Filla Giuseppe De Michele Roberto Marconi Luigi Bucci Carmine Carillo Anna Elisa Castellano Lucio Iorio Claudio Kniahynicki Francesco Rossi Giuseppe Campanella 《Journal of neurology》1992,239(6):351-353
Summary An epidemiological survey of hereditary ataxias and paraplegias was conducted in Molise, a region of Italy (335, 211 inhabitants on 1 January 1989). Total prevalence was 7.5 x 10–5 inhabitants (95% confidence limits 4.8–11.1). There were 7 patients with Friedreich's disease, 5 with early onset cerebellar ataxia with retained tendon reflexes, 4 with ataxia-telangiectasia, 9 with hereditary spastic paraplegias (2 autosomal dominant and 7 autosomal recessive cases). There was no patient with autosomal dominant cerebellar ataxia. 相似文献
56.
Giovanni Melioli Editta Baldini Maria Cristina Mingari Andrea De Maria Mario Roberto Sertoli Fausto Badellino Pier Luigi Percivale Alessandra Catturich Sergio Bertoglio Dario Civalleri Leonardo Santi Lorenzo Moretta 《International journal of cancer. Journal international du cancer》1989,43(2):231-234
In the course of a phase I trial, in which recombinant IL-2 (rIL-2) was infused intraperitoneally (i.p.) in patients with peritoneal carcinomatosis, we evaluated the effect on "tumor-associated lymphocytes" (TAL) isolated from the ascitic fluid. No major changes in the percentages of cells expressing the CD3, CD4, CD8, Leu-7, OKM1 and WT-31 antigens were detected either in TAL or in peripheral blood lymphocytes (PBL) after 7 days of rIL-2 infusion. In contrast the percentages of TAL (but not PBL) expressing surface IL-2 receptor (Tac), or LAK-1 antigen were sharply increased. Analysis of cytolytic functions showed a potentiation of the lytic activity against natural-killer (NK) sensitive K562 target cells and the de novo appearance of lytic activity against fresh melanoma cells. In one patient IFN-gamma was detected in the ascitic fluid following rIL-2 infusion. T-cell clones derived from the patient were analyzed for the IFN-gamma production. While only approximately 40% of PB-derived control clones produced medium to low amounts of IFN-gamma, all of the TAL-derived clones produced medium to high amounts of the lymphokine. 相似文献
57.
Ilaria Marigo Luigi Dolcetti Paolo Serafini Paola Zanovello Vincenzo Bronte 《Immunological reviews》2008,222(1):162-179
Summary: Emerging evidence indicates that the Achilles' heel of cancer immunotherapies is often the complex interplay of tumor-derived factors and deviant host properties, which involve a wide range of immune elements in the lymphoid and myeloid compartments. Regulatory lymphocytes, tumor-conditioned myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages, and dysfunctional and immature dendritic cells take part in a complex immunoregulatory network. Despite the fact that some mechanisms governing tumor-induced immune tolerance and suppression are starting to be better understood and their complexity dissected, little is known about the diachronic picture of immune tolerance. Based on observations of MDSCs, we present a time-structured and topologically consistent idea of tumor-dependent tolerance progression in tumor-bearing hosts. 相似文献
58.
Crosignani Pier Giorgio; De Cecco Luigi; Gastaldi Attilio; Venturini Pier Luigi; Oldani Sabina; Vegetti Walter; Semino Antonio; Commare Paolo La; Vercellini Paolo 《Human reproduction (Oxford, England)》1996,11(12):2732-2735
An open-label randomized pilot study was conducted to evaluatethe efficacy and acceptability of 6 months treatment with leuprolidein a 3-monthly versus a monthly i.m. depot injection for therelief of chronic pelvic pain in women with endometriosis. Atotal of 30 women aged 18-38 years were allocated to the 3-monthlydepot arm (n = 15) or to the monthly depot arm (n = 15) afterlaparoscopic diagnosis of pelvic endometriosis. Mean (SD) deepdys-pareunia scores according to a 03 point verbal ratingscale decreased from 1.8 (0.9) at baseline to 1.3 (0.7) at theend of treatment in the 3-monthly depot group and from 2.1 (1.2)to 13 (0.7) in the monthly depot group. Correspondingvalues in non-menstrual pain scores fell from 2.1 (0.6) to 1.1(03), and from 2.1 (0.8) to 1.2 (0.4) respectively, withoutstatistically significant differences between the groups. Serumluteinizing hormone (LH) and 17-oestradiol concentrations weresignificantly suppressed at 12 and 24 weeks compared with baselinevalues, without differences between the groups. The monthlydepot caused a slightly more marked inhibition of serum folliclestimulating hormone (FSH) levels with respect to the 3-monthlypreparation. Mean (SD) endometriosis scores at baseline andat 6-month follow-up laparoscopy were respectively 32.8 (25.1)and 12.2 (9.3) in the 3-monthly depot group and 29.0 (22.7)and 13.1 (15.3) in the monthly depot group (paired Mest, P 0.05). Mean percentage decrease in lumbar spine bone mineraldensity was 5.2% in the former and 4.9% in the latter subjects.In the 3-monthly depot group, 13 women graded the tolerabilityof their treatment schedule as good compared withseven in the monthly depot group (2 = 5.40, P = 0.02). 相似文献
59.
Luigi Marazzini Andrea Pelucchi Marina Bozzoni Berardino Mastropasqua Erminio Longhini 《Journal of clinical immunology》1985,5(3):195-203
The role of adrenergic mechanism in the pathogenesis of allergic disease is controversial. Recent experimental and clinical reports have suggested that -adrenergic blockade impairs and stimulation enhances extrarenal potassium uptake in humans. This led us to study the effect of the intravenous administration of salbutamol, a specific -2-adrenergic agonist, on serum potassium in 9 healthy subjects and in 23 patients with allergic asthma and/or rhinitis. Serum potassium fell significantly and reached a peak decline at the end of venous infusion in all the normal subjects. Seventeen atopic subjects showed a lower or absent serum K+ decrement: there was no difference between asthmatic and rhinitic patients. There was no relation among the salbutamol-induced serum potassium decrement, serum glucose increment, blood pressure and heart-rate changes, and nonspecific bronchial reactivity. These findings suggest that -2-adrenergic hyporesponsiveness is present only in some allergic patients. 相似文献
60.
This review was designed to determine from the best evidence whether there is an association between postmenopausal hormonal treatment and breast cancer risk. Also, if there is an association, does it vary according to duration and cessation of use, type of regimen, type of hormonal product or route of administration; whether there is a differential effect on risk of lobular and ductal cancer; and whether hormone treatment is associated with breast cancers that have better prognostic factors? Data sources for the review included Medline, the Cochrane Database of Systematic Reviews (Cochrane Library, 2005) and reference lists in the identified citations. Eligible citations addressed invasive breast cancer risk among postmenopausal women and involved use of the estrogen products with or without progestin that are used as treatment for menopausal symptoms. Abstracted data were demographic groupings, categories of hormone use, categories of breast cancer, two-by-two tables of exposure and outcome and adjusted odds ratios, relative risks (RRs) or hazard rates. Average estimates of risk were weighted by the inverse variance method, or if heterogeneous, using a random effects model. The average risk of invasive breast cancer with estrogen use was 0.79 [95% confidence interval (95% CI) = 0.61-1.02] in four randomized trials involving 12 643 women. The average breast cancer risk with estrogen-progestin use was 1.24 (95% CI = 1.03-1.50) in four randomized trials involving 19 756 women. The average risks reported in recent epidemiological studies were higher: 1.18 (95% CI = 1.01-1.38) with current use of estrogen alone and 1.70 (95% CI = 1.36-2.17) with current use of estrogen-progestin. The association of breast cancer with current use was stronger than the association with ever use, which includes past use. For past use, the increased breast cancer risk diminished soon after discontinuing hormones and normalized within 5 years. Reasonably adequate data do not show that breast cancer risk varies significantly with different types of estrogen or progestin preparations, lower dosages or different routes of administration, although there is a small difference between sequential and continuous progestin regimens. Epidemiological studies indicate that estrogen-progestin use increases risk of lobular more than ductal breast cancer, but the number of studies and cases of lobular cancer remains limited. Among important prognostic factors, the stage and grade in breast cancers associated with hormone use [corrected] do not differ significantly from those in non-users, but breast cancers in estrogen-progestin users are significantly more likely to be estrogen receptor (ER) positive. In conclusion, valid evidence from randomized controlled trials (RCTs) indicates that breast cancer risk is increased with estrogen-progestin use more than with estrogen alone. Epidemiological evidence involving more than 1.5 million women agrees broadly with the trial findings. Although new studies are unlikely to alter the key findings about overall breast cancer risk, research is needed, however, to determine the role of progestin, evaluate the risk of lobular cancer and delineate effects of hormone use on receptor presence, prognosis and mortality in breast cancer. 相似文献